Pharmacokinetics and Pharmacogenetics of Dabigatran
Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists. However, pharmacokinetics and pharmacogenetics of dabigatran are variable. This can affect both effectiveness and sa...
Saved in:
Main Authors: | A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2021-03-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2400 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics and bioequivalence of the generic and original dabigatran etexilate after a single dose in healthy volunteers
by: V. B. Vasilyuk, et al.
Published: (2024-10-01) -
Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01) -
Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01) -
PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01) -
DABIGATRAN ETEXILATE IN ELDERL Y PATIENTS WITH ATRIAL FIBRILLATION: WHATS NEW?
by: O. N. Tkacheva, et al.
Published: (2017-12-01)